{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T04:06:17Z","timestamp":1763179577201},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,13]]},"DOI":"10.7759\/cureus.60188","type":"journal-article","created":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T11:31:23Z","timestamp":1715599883000},"source":"Crossref","is-referenced-by-count":2,"title":["Pancreatitis After Treatment With Encorafenib, Binimetinib, and Cetuximab for BRAF V600E Mutation-Positive Colorectal Cancer"],"prefix":"10.7759","author":[{"given":"Yuika","family":"Kureyama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Hanaoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuichiro","family":"Matoba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroya","family":"Kuroyanagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0047054","article-title":"The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis","volume":"7","author":"Safaee Ardekani G","year":"2012","unstructured":"Safaee Ardekani G, Jafarnejad SM, Tan L, Saeedi A, Li G. The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis. PLoS One. 2012, 7:e47054. 10.1371\/journal.pone.0047054","journal-title":"PLoS One"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies H","year":"2002","unstructured":"Davies H, Bignell GR, Cox C, et al.. Mutations of the BRAF gene in human cancer. Nature. 2002, 417:949-54. 10.1038\/nature00766","journal-title":"Nature"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908075","article-title":"Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer","volume":"381","author":"Kopetz S","year":"2019","unstructured":"Kopetz S, Grothey A, Yaeger R, et al.. Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer. N Engl J Med. 2019, 381:1632-43. 10.1056\/NEJMoa1908075","journal-title":"N Engl J Med"},{"key":"ref4","unstructured":"Labour and Welfare Research Group on Intractable Pancreatic Diseases . (2008). Accessed. March 25, 2024: https:\/\/mhlw-grants.niph.go.jp\/project\/23075."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605177","article-title":"KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer","volume":"101","author":"Loupakis F","year":"2009","unstructured":"Loupakis F, Ruzzo A, Cremolini C, et al.. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer. 2009, 101:715-21. 10.1038\/sj.bjc.6605177","journal-title":"Br J Cancer"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25555","article-title":"Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation","volume":"128","author":"Tie J","year":"2011","unstructured":"Tie J, Gibbs P, Lipton L, et al.. Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation. Int J Cancer. 2011, 128:2075-84. 10.1002\/ijc.25555","journal-title":"Int J Cancer"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2078-6891.2015.077","article-title":"BRAF mutant colorectal cancer as a distinct subset of colorectal cancer: clinical characteristics, clinical behavior, and response to targeted therapies","volume":"6","author":"Clarke CN","year":"2015","unstructured":"Clarke CN, Kopetz ES. BRAF mutant colorectal cancer as a distinct subset of colorectal cancer: clinical characteristics, clinical behavior, and response to targeted therapies. J Gastrointest Oncol. 2015, 6:660-7. 10.3978\/j.issn.2078-6891.2015.077","journal-title":"J Gastrointest Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02459","article-title":"Binimetinib, encorafenib, and cetuximab triplet therapy for patients with BRAF V600E-mutant metastatic colorectal cancer: safety lead-in results from the Phase III BEACON Colorectal Cancer Study","volume":"37","author":"Van Cutsem E","year":"2019","unstructured":"Van Cutsem E, Huijberts S, Grothey A, et al.. Binimetinib, encorafenib, and cetuximab triplet therapy for patients with BRAF V600E-mutant metastatic colorectal cancer: safety lead-in results from the Phase III BEACON Colorectal Cancer Study. J Clin Oncol. 2019, 37:1460-9. 10.1200\/JCO.18.02459","journal-title":"J Clin Oncol"},{"key":"ref9","article-title":"[A case of BRAF V600E-mutant colorectal cancer treated effectively by encorafenib, binimetinib, and cetuximab triple therapy] [Article in Japanese]","volume":"49","author":"Sakamoto S","year":"2022","unstructured":"Sakamoto S, Tagai N, Shimada M, et al.. [A case of BRAF V600E-mutant colorectal cancer treated effectively by encorafenib, binimetinib, and cetuximab triple therapy] [Article in Japanese]. Gan To Kagaku Ryoho. 2022, 49:1145-7.","journal-title":"Gan To Kagaku Ryoho"},{"key":"ref10","article-title":"[New Treatment Strategies for BRAF Mutation-Positive Colorectal Cancer] [Article in Japanese]","volume":"48","author":"Kawakami H","year":"2021","unstructured":"Kawakami H, Ogata S. [New Treatment Strategies for BRAF Mutation-Positive Colorectal Cancer] [Article in Japanese]. Gan To Kagaku Ryoho. 2021, 48:787-95.","journal-title":"Gan To Kagaku Ryoho"},{"key":"ref11","article-title":"Colorectal Cancer Treatment Guidelines for Physicians, 2022","author":"Colorectal Cancer Study Group","year":"2022","unstructured":"Colorectal Cancer Study Group.  Colorectal Cancer Treatment Guidelines for Physicians, 2022. Kanehara Shuppan, Tokyo; 2022."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo CA","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, et al.. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981, 30:239-45. 10.1038\/clpt.1981.154","journal-title":"Clin Pharmacol Ther"},{"key":"ref13","doi-asserted-by":"crossref","DOI":"10.3862\/jcoloproctology.75.182","article-title":"A case of pathological complete remission for colon cancer with BRAF V600E mutation and MSI-high plus multiple metastasis by pembrolizumab after bevacizumab plus FOLFOXIRI therapy","volume":"75","author":"Kitagawa K","year":"2022","unstructured":"Kitagawa K, Takahashi N, Kaji M, et al.. A case of pathological complete remission for colon cancer with BRAF V600E mutation and MSI-high plus multiple metastasis by pembrolizumab after bevacizumab plus FOLFOXIRI therapy. J Japan Soc Coloproctol. 2022, 75:182-7.","journal-title":"J Japan Soc Coloproctol"},{"key":"ref14","article-title":"[\u2161.BRAF-mutated colorectal cancer-up-to-date evidence and clinical practice] [Article in Japanese]","volume":"49","author":"Okura M","year":"2022","unstructured":"Okura M, Mitani S. [\u2161.BRAF-mutated colorectal cancer-up-to-date evidence and clinical practice] [Article in Japanese]. Gan To Kagaku Ryoho. 2022, 49:1216-20.","journal-title":"Gan To Kagaku Ryoho"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/251201-pancreatitis-after-treatment-with-encorafenib-binimetinib-and-cetuximab-for-braf-v600e-mutation-positive-colorectal-cancer","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T11:31:35Z","timestamp":1715599895000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/251201-pancreatitis-after-treatment-with-encorafenib-binimetinib-and-cetuximab-for-braf-v600e-mutation-positive-colorectal-cancer"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,13]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.60188","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,13]]}}}